< Back to previous page
Researcher
Veerle Janssens
- Disciplines:Proteins, Cell division, Cell signalling, Posttranslational modifications, Cancer biology, Cancer therapy, Developmental biology, Genetics
Affiliations
- Laboratory of Protein Phosphorylation and Proteomics (Division)
Responsible
From1 Oct 2021 → Today - Laboratory of Protein Phosphorylation and Proteomics (Division)
Member
From1 Oct 2007 → Today
Projects
1 - 10 of 31
- Insights into the molecular mechanisms underlying Houge-Janssens syndrome type 1: towards treatment optionsFrom1 Nov 2025 → TodayFunding: Foundations, funds and other with scientific goal
- Identifying disease-critical cell types and pathways to guide new treatment approaches for Houge-Janssens syndrome type 2 (HJS2)From1 Oct 2025 → TodayFunding: FWO senior postdoctoral fellowship
- Molecular mechanisms underlying Houge-Janssens Syndrome type 1.From1 Feb 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Continued provision of an affordable medium-parametric cell analysis solution at the KU Leuven Flow Cytometry core facilityFrom1 Jan 2025 → TodayFunding: Own budget, for example: patrimony, inscription fees, gifts
- Continued provision of an affordable medium-parametric cell analysis solution at the KU Leuven Flow Cytometry core facilityFrom1 Jan 2025 → TodayFunding: BOF - scientific equipment program
- Activating negative regulators of KRAS signaling as a novel anticancer paradigmFrom1 Oct 2024 → TodayFunding: Fund Recuperation Fiscal Exemption, BOF - projects
- Identifying disease-critical cell types and pathways to guide new treatment approaches for Houge-Janssens syndrome type 2 (HJS2)From1 Oct 2024 → 30 Sep 2025Funding: BOF - postdoctoral mandates
- Next-generation, multi-technology immune-monitoring and easy-access spectral flow cytometryFrom1 May 2022 → TodayFunding: FWO Medium Size Research Infrastructure
- Integrated, multimodal phenotypic analysis of Ppp2r1a knockin mice: new in vivo models of syndromic PP2A-related (neuro)developmental disorders.From1 Oct 2021 → 30 Sep 2024Funding: FWO junior postdoctoral fellowship
- Insights into the disease mechanisms of PPP2R5D, PPP2R5C and PPP2R1A syndromes: towards therapeutic avenuesFrom1 Jul 2021 → 30 Jun 2025Funding: Foreign private sponsor - undefined
Publications
1 - 10 of 87
- Houge-Janssens syndrome.(2025)Published in: EUROPEAN JOURNAL OF HUMAN GENETICSISSN: 1018-4813Issue: 10Volume: 33
- The phosphatase activity of the PPP2R5D-PP2A holoenzyme modulates liprin-α1 liquid-liquid phase separation(2025)Published in: Journal of Biological ChemistryISSN: 0021-9258Issue: 7Volume: 301
- Pathogenic de novo variants in PPP2R5C cause a neurodevelopmental disorder within the Houge-Janssens syndrome spectrum(2025)Published in: American Journal of Human GeneticsISSN: 0002-9297Issue: 3Volume: 112Pages: 554 - 571
- PPP2R5E: New gene potentially involved in specific learning disorders and myopathy(2025)Published in: GeneISSN: 0378-1119Volume: 933
- PP2A phosphatase regulatory subunit PPP2R3C is a new positive regulator of the hedgehog signaling pathway(2024)Published in: Cellular SignallingISSN: 0898-6568Volume: 123
- The PPP2R1A cancer hotspot mutant p.R183W increases clofarabine resistance in uterine serous carcinoma cells by a gain-of-function mechanism(2024)Published in: Cellular OncologyISSN: 2211-3428Issue: 5Volume: 47
- PPP2R1A mutations in uterine serous carcinoma: exploring the role and predictive marker potential of hotspot mutant p.R183W(2024)
- TIPRL1 and its ATM‑dependent phosphorylation promote radiotherapy resistance in head and neck cancer(2024)Published in: Cellular OncologyISSN: 2211-3428Issue: 3Volume: 47
- Function of PP2A methylesterase-1 PME-1 in the stress response: implications for glioblastoma treatment(2023)
- Targeting radiotherapy resistance in Head and Neck Cancers: the potential biomarker role of TIPRL1 and CIP2A, two cellular inhibitors of Protein Phosphatase 2A(2023)